Nguyen Thi Bich Van, Nguyen Thanh Khiem, Nguyen Ngoc Cuong, Phan Hoang Giang, Nguyen Quang Trung, Thieu Thi Tra My, Bui Thi Phuong Thao, Tran Quoc Hoa
{"title":"Prospective evaluation of uterine artery embolization using diluted NBCA-lipiodol mixture for uterine fibroids: preliminary treatment outcomes.","authors":"Nguyen Thi Bich Van, Nguyen Thanh Khiem, Nguyen Ngoc Cuong, Phan Hoang Giang, Nguyen Quang Trung, Thieu Thi Tra My, Bui Thi Phuong Thao, Tran Quoc Hoa","doi":"10.1186/s42155-026-00782-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine the safety and effectiveness of uterine artery embolization using NBCA - lipiodol mixture via radial artery access for the treatment of uterine fibroids.</p><p><strong>Methods: </strong>Forty patients underwent uterine artery embolization with NBCA mixed with lipiodol (1:10). The uterine fibroid volumes were determined on magnetic resonance imaging before and 3-6 months after the procedure. We analyzed the following parameters: dominant fibroid volume, hemoglobin levels, symptoms before treatment, after embolization, and complications.</p><p><strong>Results: </strong>The mean age was 41 ± 6.5 years and mean uterine volume prior to treatment, 137.7 ± 104.3 ml. After 3-6 months embolization, the mean fibroid volume decreased from 137.7 ± 104.3 cm<sup>3</sup> to 51 ± 54.3 cm<sup>3</sup> (p < 0.001), corresponding to a mean volume reduction of 64.7 ± 22.7%. Hemoglobin levels also significantly increased (p < 0.001). No major intraprocedural adverse events were observed. Major complications occurred in 2.5% (fibroid expulsion). The minor complications rate was 20%, related to post-embolization syndrome (pain). The late adverse events occurred in 10%: alopecia (7.5%), vaginal dryness (2.5%). The length of hospital stay was 1.9 ± 0.8 days. Clinical symptomatic improvement was observed in 100% and symptoms were resolved in 87.5%.</p><p><strong>Conclusion: </strong>This prospective single-arm study suggests that UAE using a diluted NBCA-lipiodol mixture is feasible and appears to be safe, with encouraging early clinical and MRI outcomes. However, the short follow-up period, absence of a comparative control group, and lack of direct assessment of fibroid infarction preclude definitive conclusions regarding its efficacy or its role relative to established particulate embolic agents.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"9 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646211/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CVIR Endovascular","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42155-026-00782-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This study aimed to determine the safety and effectiveness of uterine artery embolization using NBCA - lipiodol mixture via radial artery access for the treatment of uterine fibroids.
Methods: Forty patients underwent uterine artery embolization with NBCA mixed with lipiodol (1:10). The uterine fibroid volumes were determined on magnetic resonance imaging before and 3-6 months after the procedure. We analyzed the following parameters: dominant fibroid volume, hemoglobin levels, symptoms before treatment, after embolization, and complications.
Results: The mean age was 41 ± 6.5 years and mean uterine volume prior to treatment, 137.7 ± 104.3 ml. After 3-6 months embolization, the mean fibroid volume decreased from 137.7 ± 104.3 cm3 to 51 ± 54.3 cm3 (p < 0.001), corresponding to a mean volume reduction of 64.7 ± 22.7%. Hemoglobin levels also significantly increased (p < 0.001). No major intraprocedural adverse events were observed. Major complications occurred in 2.5% (fibroid expulsion). The minor complications rate was 20%, related to post-embolization syndrome (pain). The late adverse events occurred in 10%: alopecia (7.5%), vaginal dryness (2.5%). The length of hospital stay was 1.9 ± 0.8 days. Clinical symptomatic improvement was observed in 100% and symptoms were resolved in 87.5%.
Conclusion: This prospective single-arm study suggests that UAE using a diluted NBCA-lipiodol mixture is feasible and appears to be safe, with encouraging early clinical and MRI outcomes. However, the short follow-up period, absence of a comparative control group, and lack of direct assessment of fibroid infarction preclude definitive conclusions regarding its efficacy or its role relative to established particulate embolic agents.